肺气肿新疗法开发商Apreo Health完成1.3亿美元B轮融资，推进重度肺气肿突破性气道支架的关键试验与早期商业化-动脉网

Apreo Health Closes $130 Million Series B Financing to Advance Pivotal Trial and Early Commercialization of Breakthrough Airway Scaffold for Severe Emphysema

vcaonline 等信源发布 2025-08-07 23:21



可切换为仅中文







Apreo Health Closes $130 Million Series B Financing to Advance Pivotal Trial and Early Commercialization of Breakthrough Airway Scaffold for Severe Emphysema

Apreo Health完成1.3亿美元B轮融资，以推进针对重度肺气肿的突破性气道支架的关键试验和早期商业化。

MENLO PARK, Calif., August 7, 2025-- Apreo Health, a clinical-stage medical device company developing a novel treatment for severe emphysema, today announced the closing of an oversubscribed $130 million Series B financing round. The financing was co-led by new investors Bain Capital Life Sciences and Norwest, with participation from new investors F-Prime and Intuitive Ventures.

门洛帕克，加利福尼亚州，2025年8月7日——Apreo Health是一家临床阶段的医疗器械公司，致力于开发一种用于治疗严重肺气肿的新型疗法，今天宣布完成了超额认购的1.3亿美元B轮融资。本轮融资由新投资者贝恩资本生命科学和Norwest共同领投，新投资者F-Prime和Intuitive Ventures也参与其中。

Returning investors Lightstone Ventures and Santé Ventures also participated in the round..

回头投资者Lightstone Ventures和Santé Ventures也参与了这一轮。

The Series B financing will primarily support BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3), a multicenter, randomized controlled trial designed to evaluate the safety and efficacy of the Apreo BREATHE Airway Scaffold, a bronchoscopically delivered implant designed to relieve lung hyperinflation by releasing trapped air in patients with severe emphysema.

B轮融资将主要用于支持BREATHE-3（支气管镜下释放肺气肿过度充气肺中被困空气的研究3），这是一项多中心、随机对照试验，旨在评估Apreo BREATHE气道支架的安全性和有效性。该支架是一种通过支气管镜植入的装置，旨在通过释放严重肺气肿患者肺部的被困空气来缓解肺过度充气。

Additionally, the Series B financing will fund regulatory activities related to BREATHE-3 and early commercialization efforts to demonstrate strong market potential..

此外，B轮融资还将为与BREATHE-3相关的监管活动提供资金，并支持早期商业化努力，以展示强大的市场潜力。

“We are incredibly grateful for the support from this world-class syndicate of investors and their desire to partner to redefine the standard of care in emphysema,” said Karun Naga, CEO of Apreo Health. “More than three million Americans are affected by severe emphysema, yet fewer than 1% receive interventional treatment—a stark reflection of limitations of currently available treatments.

“我们非常感谢来自这个世界级投资者财团的支持，以及他们希望合作重新定义肺气肿护理标准的愿望，”Apreo Health首席执行官Karun Naga表示。“超过三百万美国人受到严重肺气肿的影响，但只有不到1%的人接受介入治疗——这清楚地反映了当前可用治疗手段的局限性。”

Our BREATHE Scaffold offers a fundamentally different approach: a novel implant designed to gently release air trapped in affected lungs, with potential for much broader adoption. This financing marks a significant milestone that enables us to complete a robustly designed pivotal trial and continue advancing toward expanded access for this severely underserved population.”.

我们的BREATHE支架提供了一种完全不同的方法：一种设计新颖的植入物，能够温和地释放受累肺部的积气，具有更广泛的应用潜力。此次融资标志着一个重要里程碑，使我们能够完成一个精心设计的关键试验，并继续朝着为这一严重服务不足的群体扩大使用范围的目标迈进。"

“Apreo is addressing one of the most underserved populations in chronic obstructive pulmonary disease (COPD) and doing so with clinical clarity and executional rigor,” said Zack Scott, M.D., general partner, Norwest. “This is a step-change in how we approach emphysema care. The solution is both elegant in design and built for broad, scalable delivery.

“Apreo正在解决慢性阻塞性肺疾病（COPD）中服务最不足的人群之一，并且在临床清晰度和执行严谨性方面表现出色，”Norwest的普通合伙人扎克·斯科特（Zack Scott）博士说道。“这是我们在肺气肿护理方法上的一次重大转变。该解决方案设计优雅，并且能够广泛、规模化地实施。”

We’re proud to support Apreo in this next chapter.”.

我们很自豪能在下一章中支持Apreo。

“We are excited to partner with Apreo at this key inflection point in the company’s evolution as it advances the BREATHE Airway Scaffold into late-stage development,” said Nicholas Downing, M.D., a Managing Director at Bain Capital Life Sciences. “The device has the potential to deliver meaningful clinical benefit to a broader patient population—addressing the significant unmet need that exists today in chronic obstructive pulmonary disease.”.

“我们很高兴在Apreo公司发展的这一关键转折点与其合作，因为其正在将BREATHE气道支架推进到后期开发阶段，”贝恩资本生命科学的董事总经理尼古拉斯·唐宁博士表示。“该设备有潜力为更广泛的患者群体带来显著的临床益处——解决当今慢性阻塞性肺疾病中未被满足的重大需求。”

About Apreo Health

关于Apreo健康中心

Apreo Health is redefining interventional pulmonology with a non-destructive, tissue-sparing solution for severe emphysema—one of the most under-treated and misunderstood diseases in medicine. Formed at The Foundry, one of the world’s premier medtech incubators, and backed by top-tier investors, Apreo is led by a team with deep expertise in both pulmonary medicine and medical device innovation.

Apreo Health 正在通过一种非破坏性、保留组织的解决方案重新定义介入肺病学，用于治疗严重肺气肿——这是医学界最被忽视和误解的疾病之一。Apreo 源自全球顶级医疗技术孵化器之一 The Foundry，并受到一流投资者的支持，由在肺科医学和医疗设备创新方面拥有深厚专业知识的团队领导。

The company is advancing a therapy purpose-built to expand access, simplify delivery, and transform the treatment pathway for patients with severe emphysema. Privately held, the company is backed by Bain Capital Life Sciences, Norwest, F-Prime, Intuitive Ventures, Lightstone Ventures, Santé Ventures, and The Foundry..

该公司正在推进一种专为扩大患者获得途径、简化治疗输送并改变重度肺气肿患者治疗路径而设计的疗法。该公司为私人持有，由贝恩资本生命科学、西北投资、F-Prime、直觉创投、光石创投、桑特创投和The Foundry支持。

About Chronic Obstructive Pulmonary Disease & Emphysema

关于慢性阻塞性肺疾病和肺气肿

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death and the eighth leading cause of poor health worldwide, according to the World Health Organization (WHO). The U.S. Centers for Disease Control and Prevention (CDC) estimates that nearly 16 million Americans have been diagnosed with COPD, with millions more undiagnosed.

根据世界卫生组织 (WHO) 的数据，慢性阻塞性肺疾病 (COPD) 是全球第四大死亡原因，也是全球第八大致病原因。美国疾病控制与预防中心 (CDC) 估计，近 1600 万美国人被诊断出患有慢性阻塞性肺病，另有数百万人尚未确诊。

Emphysema, a severe form of COPD characterized by the destruction of lung air sacs, affects approximately three million people in the U.S. and is a leading contributor to COPD-related disability and mortality. Today, fewer than 1% of patients with emphysema-related hyperinflation receive interventional care..

肺气肿是一种严重的慢性阻塞性肺病（COPD），其特征是肺泡的破坏，影响美国约三百万人，是导致COPD相关残疾和死亡的主要因素。如今，不到1%的与肺气肿相关的过度充气患者接受介入治疗。

About BREATHE Airway Scaffold

关于BREATHE气道支架

The BREATHE (Bronchoscopic RElease of Air THErapy) Airway Scaffold is a lung implant designed to release air from a hyperinflated lung associated with severe emphysema. The proprietary scaffold is uniquely designed to resist foreign body reaction and promote durability of effect. The device was granted U.S.

BREATHE（支气管镜下空气释放疗法）气道支架是一种肺部植入物，旨在释放与严重肺气肿相关的过度充气肺中的空气。该专有支架的独特设计能够抵抗异物反应并促进效果的持久性。该设备已获得美国授予。

Food and Drug Administration (FDA) Breakthrough Device Designation in May 2024..

美国食品药品监督管理局（FDA）于2024年5月授予突破性医疗器械认定。

The BREATHE Airway Scaffold is an Investigational Device—limited by Federal (or United States) law to investigational use.

BREATHE气道支架是一种研究性装置——根据联邦（或美国）法律限制为研究性使用。

Contacts

联系人

Investor Contact:

投资者联系方式：

Karun Naga

卡鲁恩·纳加

Apreo Health